GLP-1 Weight Loss: Eligibility & Safety

GLP-1 medications (semaglutide and tirzepatide) are prescribed for weight management in adults who meet specific clinical criteria. You may be eligible if you meet any of the following:

Non-diabetic patients are eligible. You do not need to have Type 2 diabetes to qualify for GLP-1 weight loss medication. Both semaglutide (Wegovy) and tirzepatide (Zepbound) have FDA approval specifically for weight management in non-diabetic patients.

Age requirement: 18 years or older.

GLP-1 medications are not appropriate for everyone. You should not take semaglutide or tirzepatide if you have any of the following:

• Type 1 diabetes — GLP-1 medications are not indicated for Type 1 diabetes
• Uncontrolled Type 2 diabetes on insulin — requires coordination with your existing care team
• Recent stroke or heart attack — within the past 6 months
• History of pancreatitis — GLP-1 medications may increase risk of pancreatitis
• Active cancer or recent remission — within the past 5 years
• Eating disorders — current or history of anorexia, bulimia, or other eating disorders
• Pregnancy, breastfeeding, or planning pregnancy — GLP-1 medications should be discontinued before conception
• Medullary thyroid cancer or MEN2 — personal or family history (boxed warning)

This is not an exhaustive list. Your VivioMD provider will conduct a thorough review of your health history to determine eligibility. Always disclose all current medications and health conditions during your consultation.

Both semaglutide and tirzepatide share similar side effect profiles. Most side effects are gastrointestinal and tend to subside as your body adjusts to the medication:

• Nausea — the most commonly reported side effect, especially during dose titration. Typically mild to moderate and improves over time.
• Decreased appetite — an expected therapeutic effect of the medication, contributing to weight loss.
• Digestive changes — diarrhea, constipation, or abdominal discomfort may occur, particularly during the first few weeks.
• Injection site reactions — for injectable forms, mild redness, swelling, or itching at the injection site. Does not apply to ODT or oral formulations.

Gradual dose titration (starting low and increasing slowly) is the primary strategy for minimizing side effects. Your VivioMD provider manages this progression based on your tolerance.

Important: Both semaglutide and tirzepatide carry a boxed warning regarding thyroid C-cell tumors observed in animal studies. These medications are contraindicated in patients with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

VivioMD provides ongoing clinical oversight throughout your treatment:

• Monthly follow-ups (initial phase): During dose titration, your provider checks in monthly to assess tolerance, manage side effects, and adjust your dose.
• Quarterly follow-ups (maintenance): Once stabilized on your target dose, follow-ups shift to every three months.
• Provider access between visits: Contact your provider if you experience severe side effects or have concerns at any time.

All clinical care is provided by licensed clinicians through OpenLoop Healthcare Partners. Follow-up care is included in your $149/mo subscription.